Please use this identifier to cite or link to this item:
https://scholarhub.balamand.edu.lb/handle/uob/7095
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Haidar, Mohamad | en_US |
dc.contributor.author | Kassas, Mutaz | en_US |
dc.contributor.author | Chehade, Feras | en_US |
dc.contributor.author | Chahinian, Rita | en_US |
dc.contributor.author | Abi-Ghosn, Jean | en_US |
dc.contributor.author | Haddad, Marwan M | en_US |
dc.date.accessioned | 2023-11-06T09:02:04Z | - |
dc.date.available | 2023-11-06T09:02:04Z | - |
dc.date.issued | 2023-11-01 | - |
dc.identifier.issn | 01433636 | - |
dc.identifier.uri | https://scholarhub.balamand.edu.lb/handle/uob/7095 | - |
dc.description.abstract | In previous literature, 18 F-FDG-PET/ CT imaging significantly impacted differentiated thyroid cancer (DTC) therapy. Low thyroglobulin (Tg) levels and negative Iodine-131 (131I) whole-body scan (WBS), along with negative 18 F-FDG-PET/ CT, suggested a lesser likelihood of active illness. Positive 18 F-FDG-PET/CT findings, however, were associated with a variety of signs of local recurrence and regional or distant metastases in patients with suspected WBS. We aim to evaluate the utility of 18 F-FDG-PET/CT in managing DTC patients with negative 131I post-therapy WBS and elevated Tg. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | National Library of Medicine | en_US |
dc.subject | 18 F-FDG PET/CT | en_US |
dc.subject | Differentiated thyroid cancer | en_US |
dc.subject | Radioactive iodine | en_US |
dc.subject | Thyroglobulin | en_US |
dc.subject | Whole body scan | en_US |
dc.title | The role of 18 F-FDG-PET/CT in the management of differentiated thyroid cancer | en_US |
dc.type | Journal Article | en_US |
dc.identifier.doi | 10.1097/MNM.0000000000001758 | - |
dc.identifier.pmid | 37706259 | - |
dc.identifier.scopus | 2-s2.0-85174911746 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85174911746 | - |
dc.contributor.affiliation | Faculty of Medicine | en_US |
dc.description.volume | 44 | en_US |
dc.description.issue | 11 | en_US |
dc.description.startpage | 1046 | en_US |
dc.description.endpage | 1052 | en_US |
dc.date.catalogued | 2023-11-06 | - |
dc.description.status | Published | en_US |
dc.identifier.openURL | https://journals.lww.com/nuclearmedicinecomm/fulltext/2023/11000/the_role_of_18f_fdg_pet_ct_in_the_management_of.15.aspx | en_US |
dc.relation.ispartoftext | Nuclear Medicine Communications | en_US |
Appears in Collections: | Faculty of Medicine |
SCOPUSTM
Citations
1
checked on Sep 7, 2024
Record view(s)
31
checked on Sep 7, 2024
Google ScholarTM
Check
Altmetric
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.